Arecor Therapeutics PLC Arecor Granted Key U.S Patent (6673F)
23 March 2022 - 6:00PM
UK Regulatory
TIDMAREC
RNS Number : 6673F
Arecor Therapeutics PLC
23 March 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN
PRODUCTS
Further strengthens the Company's extensive patent portfolio
protecting its proprietary Arestat(TM) technology and diabetes
product portfolio
Cambridge, UK, 23 March 2022: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, is pleased to announce that the United
States Patent and Trademark Office has granted a patent ( US
11278624 ) protecting novel formulations of the Group's proprietary
insulin products, AT247 and AT278.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented :
"Arecor's novel insulin products, based on a combination of
existing insulin analogues and our highly innovative formulation
science, have potential to improve convenience, compliance and
enable more effective management of blood glucose for people living
with type 1 and type 2 diabetes. As the clinical validation of the
superiority of these products compared to current gold standard
prandial insulins continues, we are also advancing the intellectual
property protection for these products. This recently granted US
patent, the first within the Group's comprehensive insulin IP
strategy, is a significant milestone, and we will continue to
strengthen our IP portfolio with additional patent applications
already in progress."
Arecor has invested in building a strong patent portfolio to
protect the Arestat(TM) technology platform and its proprietary
pipeline products. The Group's intellectual property (IP) portfolio
currently comprises 36 patent families, including >50 granted
patents in Europe, the US and in other key territories. As part of
this strategy, Arecor has robust IP directed to the novel insulin
compositions that protect different aspects of AT247 and AT278
formulations, as well as their specific properties and methods of
use. Arecor's strategy is to generate a fortress of both narrow and
broad interrelated IP rights that cover the features of these
products. US 11278624 i s the first granted US patent within the
Group's comprehensive insulin IP strategy.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
.
For further details please see our website, www.arecor.com
About Arestat(TM)
The Arestat(TM) technology enables superior product profiles
across a broad range of therapies, including various types of
biopharmaceuticals and specialty hospital products. In addition to
its internal portfolio of superior proprietary products in diabetes
and other indications, Arecor leverages the Arestat(TM) technology
in partnerships with leading pharmaceutical and biotechnology
companies to deliver enhanced formulations of their therapeutic
products under a technology licensing model .
About AT247
AT247 is an ultra-rapid insulin that aims to accelerate insulin
absorption, post injection, to enable more effective management of
blood glucose levels for people living with diabetes, particularly
around difficult to manage mealtimes. Early clinical evidence
suggests that AT247 may facilitate a fully closed loop artificial
pancreas, a potentially life changing treatment option for people
living with diabetes, and a US Phase I clinical trial is currently
underway investigating the potential of the product when delivered
by continuous subcutaneous infusion via insulin pump.
About AT278
AT278 is Arecor's ultra-concentrated, ultra-rapid acting insulin
designed to accelerate the absorption of insulin post injection, to
enable more effective management of blood glucose levels to the
increasing number of people with diabetes with high daily insulin
requirements (>200 units/day), whilst maintaining the
convenience and compliance benefits of being able to deliver these
high insulin doses in a lower injection volume via a single
injection. A truly rapid acting concentrated insulin is a critical
step towards the advancement and miniaturisation of the next
generation of insulin delivery devices.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCJTMRTMTITBFT
(END) Dow Jones Newswires
March 23, 2022 03:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024
